Lumbar Spine Manipulation Versus Pharmacological Therapy in Young Women With Primary Dysmenorrhea
Short-term Effects of Lumbar Spine Manipulation Versus Pharmacological Therapy in Young Women With Primary Dysmenorrhea: a Randomized Controlled Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presented with persistent primary dysmenorrhea lasting for three or more consecutive menstrual periods
- Presented menstrual cycles no longer than 35 days
Exclusion Criteria:
- Presented any other gynecological pathologies
- Systemic diseases
- Previous surgical interventions for gynecological complaints
- Depression
- Were receiving any other treatment for primary dysmenorrhea.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lumbar spine manipulation
Application of lumbar spine manipulation by a physical therapist.
|
Lumbar spine manipulation
|
|
Active Comparator: Lumbar spine manipulation plus pharmacological therapy
Application of lumbar spine manipulation by a physical therapist along with pharmacological therapy.
|
Lumbar spine manipulation
hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
|
|
Active Comparator: Pharmacological therapy
Application of pharmacological therapy
|
hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain intensity
Time Frame: Change from baseline at 3 days
|
Pain intensity measured with a visual analogue scale
|
Change from baseline at 3 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pressure pain threshold measured in tibialis malleolus
Time Frame: Change from baseline at 3 days
|
Pressure pain threshold measured with an algometer in tibialis malleolus
|
Change from baseline at 3 days
|
|
Pressure pain threshold measured in peroneal malleolus
Time Frame: Change from baseline at 3 days
|
Pressure pain threshold measured with an algometer in peroneal malleolus
|
Change from baseline at 3 days
|
|
Low-back related disability
Time Frame: Change from baseline at 1 month
|
Low-back related disability measured with the Oswestry Disability Index
|
Change from baseline at 1 month
|
|
Anxiety and depression
Time Frame: Change from baseline at 1 month
|
Anxiety and depression measured with the Hospital Anxiety and Depression Scale
|
Change from baseline at 1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Pain
- Neurologic Manifestations
- Menstruation Disturbances
- Pelvic Pain
- Dysmenorrhea
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antiemetics
- Gastrointestinal Agents
- Adjuvants, Anesthesia
- Mydriatics
- Ibuprofen
- Scopolamine
Other Study ID Numbers
Other Study ID Numbers
- 2111730
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Women With Primary Dysmenorrhea
-
NCT07352982RecruitingPrimary Dysmenorrhea | Women | Transcutaneous Tibial Nerve Stimulation
-
NCT07520136Not yet recruiting
-
NCT07436507Not yet recruiting
-
NCT07239232RecruitingPrimary Dysmenorrhea
-
NCT07525102Completed
-
NCT07378475Not yet recruiting
-
NCT07307222Not yet recruitingPrimary Dysmenorrhea
-
NCT07308119CompletedPrimary Dysmenorrhea
-
NCT07354451RecruitingPrimary Dysmenorrhea (PD)
Clinical Trials on Lumbar spine manipulation
-
NCT04646018Completed
-
NCT03101956CompletedPatellofemoral Pain Syndrome | Anterior Knee Pain Syndrome
-
NCT02558855Completed
-
NCT07037641CompletedSpinal Manipulation | Chiropractic | Lumbal Disc Herniation
-
NCT01975311CompletedPatellofemoral Pain Syndrome
-
NCT02245425Completed
-
NCT06294132Recruiting
-
NCT01872676Completed
-
NCT02972710Suspended